Seagen announced that the U.S. Food and Drug Administration has granted accelerated approval to TUKYSA in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. TUKYSA is approved under the FDA’s Accelerated Approval Program based on tumor response rate and durability of response from the phase 2 MOUNTAINEER clinical trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This is the first FDA-approved treatment in HER2-positive metastatic colorectal cancer. The FDA previously granted Breakthrough Therapy Designation and Priority Review for TUKYSA in this setting. "Historically, patients with HER2-positive metastatic colorectal cancer who have progressed following frontline therapy have had poor outcomes," said John Strickler, M.D., associate professor of medicine, Duke University Medical Center, and lead investigator for the MOUNTAINEER trial. "The FDA approval of a chemotherapy-free combination regimen that specifically targets HER2 is great news for these patients."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SGEN:
- Pieris Pharmaceuticals announces $5M milestone from Seagen
- Seagen, Astellas and Merck announce FDA acceptance of sBLA in urothelial cancer
- Astellas, Seagen, and Merck announce priority review for Padcev and Keytruda
- Seagen announces results from Phase 2 trial of ADCETRIS
- Roche bladder cancer indication withdrawal positive for Seagen, says Guggenheim